| 摘要 |
The invention concerns a marker for low-grade inflammation and metabolic syndrome (MS) and MS-related diseases and/or low-grade inflammation-related diseases such as cardiovasculardisease, ischemic heart disease and type 2 di abetes. More particularly it concerns the measurement of the concentration o f soluble urokinase plasminogen activator receptor (suPAR) in human biologic al fluids (sputum, cystic fluid, ascites, serum, plasma, urine) as a tool of diagnosing and/or prognosticating low-grade inflammation and metabolic synd rome and the risk of development of the related diseases such as cancer, car diovascular disease, ischemic heart disease and type 2 diabetes.
|
